Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10891834 | 0.70 | NPBWR1 (0.51) | HIF1ASNCAALDH1A1TSHRNPBWR1 | |
| Bromide SCHEMBL386471 | 0.69 | HIF1A (0.43) | HIF1ASNCAALDH1A1TSHR | |
| Bromide SCHEMBL8331435 | 0.69 | SNCA (0.64) | HIF1ASNCATAAR1APPALDH1A1 | |
| Bromide SCHEMBL15635739 | 0.68 | HIF1A (0.46) | HIF1ASNCAAPPALDH1A1CYP1A2 | |
| SCHEMBL6002649 | 0.68 | RAB9A (0.51) | — | |
| SCHEMBL14285662 | 0.68 | TRPA1 (0.39) | TAAR1CYP1A2TSHR | |
| Bromide SCHEMBL2459236 | 0.67 | SNCA (0.56) | HIF1ASNCAAPPALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11630562 | 0.67 | HIF1A (0.36) | HIF1ASNCAALDH1A1CYP1A2CYP2D6 | |
| Bromide SCHEMBL7630241 | 0.67 | HIF1A (0.40) | HIF1ASNCAAPPALDH1A1CYP1A2 | |
| Bromide SCHEMBL2446627 | 0.66 | HIF1A (0.55) | HIF1ASNCATAAR1APPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060046966-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| US-6995142-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1329457-B1 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMA (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6906198-B1 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1073672-B1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMA (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1329457-A2 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMACEUTICALS, INC. (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030130204-A1 | Antipicornaviral compounds and compositons, their pharmaceutical uses, and materials for their synthesis | DRAGOVICH PETER SCOTT (US) | 2003-07-10 | — | — | US | disclosed |
| US-6531452-B1 | Peptide-like and peptidomimetic compounds that inhibit enzymatic activity of picornaviral 3C proteases and inhibit picornavirus replication | AGOURON PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1073672-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057135-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046966-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | HIF1A 3378/4885SNCA 4601/4885TAAR1 4841/4885 |
| US-20030130204-A1 | Antipicornaviral compounds and compositons, their pharmaceutical uses, and materials for their synthesis | SARNP, RNASE1, SERPINA3 | HIF1A 3115/4885SNCA 4461/4885TAAR1 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.